Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 38 of 38 entries
View as:

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

Phase: N/A Priority: Normal
NCT ID: NCT02780362 Org: User:
Start: 04/30/16 End: 04/30/16 Due: 04/30/17

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

Phase: N/A Priority: Normal
NCT ID: NCT02857946 Org: User:
Start: 02/29/16 End: 04/30/16 Due: 04/30/17

Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The Netherlands)

Phase: N/A Priority: Normal
NCT ID: NCT04854460 Org: User:
Start: 01/28/21 End: 03/22/21 Due: 03/22/22

Bioequivalence Study of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Versus Vigil 200 mg Tablets (Teva GmbH, Germany)

Phase: N/A Priority: Normal
NCT ID: NCT05855187 Org: User:
Start: 11/15/22 End: 01/10/23 Due: 01/10/24

A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)

Phase: N/A Priority: Normal
NCT ID: NCT02605798 Org: User:
Start: 08/31/15 End: 10/31/15 Due: 10/31/16

Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmaceutical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

Phase: N/A Priority: Normal
NCT ID: NCT02756936 Org: User:
Start: 02/29/16 End: 03/31/16 Due: 03/31/17

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

Phase: N/A Priority: Normal
NCT ID: NCT02675127 Org: User:
Start: 12/31/15 End: 12/31/15 Due: 12/31/16

Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)

Phase: N/A Priority: Normal
NCT ID: NCT04476966 Org: User:
Start: 01/20/20 End: 05/11/20 Due: 05/11/21

Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)

Phase: N/A Priority: Normal
NCT ID: NCT05006768 Org: User:
Start: 05/05/21 End: 06/24/21 Due: 06/24/22

A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

Phase: N/A Priority: Normal
NCT ID: NCT04039958 Org: User:
Start: 04/05/17 End: 05/28/17 Due: 05/28/18

A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)

Phase: N/A Priority: Normal
NCT ID: NCT02491450 Org: User:
Start: 02/28/15 End: 02/28/15 Due: 02/28/16

Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

Phase: N/A Priority: Normal
NCT ID: NCT05491330 Org: User:
Start: 08/21/22 End: 10/27/22 Due: 10/27/23

Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)

Phase: N/A Priority: Normal
NCT ID: NCT05798715 Org: User:
Start: 11/29/22 End: 01/13/23 Due: 01/13/24